Ray Dalio Bridgewater Associates
Ray Dalio is the founder of Bridgewater Associates, one of the world’s largest hedge funds, known for its unique “principles-based” culture and systematic investment approach. Dalio’s investment philosophy emphasizes diversified portfolios, risk parity, and the importance of understanding economic cycles in shaping investment decisions. He has authored several books, including “Principles: Life & Work,” in which he details his management philosophies, personal experiences, and life lessons.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core MSCI Emerging Markets ETF
IEMG
|
+$89.7M |
| 2 |
Cummins
CMI
|
+$35.2M |
| 3 |
Royal Bank of Canada
RY
|
+$32.9M |
| 4 |
Toll Brothers
TOL
|
+$32.7M |
| 5 |
Toronto Dominion Bank
TD
|
+$31.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$188M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$147M |
| 3 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$76M |
| 4 |
NFX
Newfield Exploration
NFX
|
+$32.1M |
| 5 |
Procter & Gamble
PG
|
+$30.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 3.42% |
| 2 | Healthcare | 2.95% |
| 3 | Consumer Discretionary | 2.83% |
| 4 | Energy | 2.39% |
| 5 | Industrials | 2.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HRC
351
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $547K | 0.01% |
6,268
-4,491
| -42% | -$399K |
|
352
Idexx Laboratories
IDXX
$46.2B
| $545K | 0.01% |
2,501
-2,994
| -54% | -$617K |
|
|
LPNT
353
DELISTED
LifePoint Health, Inc.
LPNT
| $545K | 0.01% |
11,164
-8,088
| -42% | -$419K |
|
354
Verisk Analytics
VRSK
$25B
| $543K | 0.01% |
5,048
+1,899
| +60% | +$202K |
|
|
PDCO
355
DELISTED
Patterson Companies, Inc.
PDCO
| $543K | 0.01% |
23,959
-17,479
| -42% | -$394K |
|
356
Tenet Healthcare
THC
$21.1B
| $534K | 0.01% |
15,905
-22,753
| -59% | -$707K |
|
357
Cincinnati Financial
CINF
$27.1B
| $532K | 0.01% |
7,962
+4,505
| +130% | +$320K |
|
358
Bio-Rad Laboratories Class A
BIO
$9.42B
| $529K | 0.01% |
1,832
-1,777
| -49% | -$491K |
|
359
Service Corp International
SCI
$11.6B
| $523K | 0.01% |
14,619
-9,003
| -38% | -$334K |
|
360
Teva Pharmaceuticals
TEVA
$41.2B
| $516K | 0.01% |
21,200
| – | – |
|
361
Air Products & Chemicals
APD
$67.6B
| $513K | 0.01% |
+3,294
| New | +$539K |
|
362
L3Harris
LHX
$53.4B
| $513K | 0.01% |
+3,550
| New | +$550K |
|
|
SINA
363
DELISTED
Sina Corp
SINA
| $513K | 0.01% |
+6,056
| New | +$564K |
|
364
Cisco
CSCO
$479B
| $500K | 0.01% |
+11,611
| New | +$507K |
|
|
WCG
365
DELISTED
Wellcare Health Plans, Inc.
WCG
| $495K | ﹤0.01% |
2,010
-2,302
| -53% | -$501K |
|
366
Jabil
JBL
$35.8B
| $491K | ﹤0.01% |
17,766
+4,021
| +29% | +$113K |
|
367
Citigroup
C
$226B
| $488K | ﹤0.01% |
7,289
-22,874
| -76% | -$1.57M |
|
368
Unum
UNM
$14.3B
| $481K | ﹤0.01% |
13,001
-24,659
| -65% | -$1.03M |
|
369
Hartford Financial Services
HIG
$39.3B
| $478K | ﹤0.01% |
+9,346
| New | +$490K |
|
370
Moody's
MCO
$82.7B
| $478K | ﹤0.01% |
2,805
-1,427
| -34% | -$242K |
|
371
B2Gold
BTG
$6.64B
| $475K | ﹤0.01% |
183,209
+19,561
| +12% | +$53.5K |
|
|
UFS
372
DELISTED
DOMTAR CORPORATION (New)
UFS
| $445K | ﹤0.01% |
+9,327
| New | +$432K |
|
373
KeyCorp
KEY
$24.4B
| $441K | ﹤0.01% |
22,573
-53,916
| -70% | -$1.08M |
|
|
PCH
374
DELISTED
PotlatchDeltic
PCH
| $438K | ﹤0.01% |
+8,620
| New | +$437K |
|
|
BMS
375
DELISTED
Bemis
BMS
| $432K | ﹤0.01% |
+10,233
| New | +$441K |
|
Similar funds
Ray Dalio's Q2 2018 Portfolio in Review
As of Q2 2018, Ray Dalio held 552 positions worth $10B, down 4.6% from $10.5B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Ray Dalio's Q2 2018 filing shows 92 new, 126 increased, 226 reduced and 92 closed positions. Its largest new stake was Cummins: 235,261 shares worth $31.3M. The largest sale was iShares MSCI Emerging Markets ETF, an estimated $188M.
By sector, the portfolio is most concentrated in Financials at 3.4% of assets, up from 2% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Ray Dalio's largest Q2 2018 buy was Cummins: 235,261 shares worth $31.3M.
- Ray Dalio added most to iShares Core MSCI Emerging Markets ETF in Q2 2018, an estimated $89.7M increase.
- Ray Dalio's biggest Q2 2018 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $188M.
- Ray Dalio fully exited Procter & Gamble in Q2 2018, selling an estimated $30.9M.
- Ray Dalio's ten largest holdings make up 70% of its $10B portfolio in Q2 2018.
- Ray Dalio opened 92 new positions and closed 92 in Q2 2018.
- Ray Dalio's portfolio value fell 4.6% quarter-over-quarter to $10B.
Based on Bridgewater Associates's 13F filing for Q2 2018, filed 13 Aug 2018.